Exploring Non‐Covalent Pin1‐PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.71850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Lorenzo Meneghelli und 9 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, BioCIS, CY Cergy Paris Université, Cergy Pontoise, France. Hauptthemen laut MEDLINE: NIMA-Interacting Peptidylprolyl Isomerase, Multiple Myeloma, Enzyme Inhibitors, Antineoplastic Agents. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ANR (Agence Nationale de la Recherche), CY Initiative.
Abstract (Originalsprache)
Pin1 is a peptidyl‐prolyl isomerase involved in key signalling pathways and upregulated in different cancers, including Multiple Myeloma (MM), where it is linked to poor prognosis/drug resistance. Despite its therapeutic relevance, Pin1 remains challenging to target with conventional inhibitors thereby motivating interest in Targeted Protein Degradation (TPD) strategies. All reported Pin1‐PROTACs rely on covalent Pin1 ligands, leaving non‐covalent degraders largely unexplored. Since PROTACs (PROteolysis TArgeting Chimeras) act catalytically/reversibly, non‐covalent designs are attractive. Here, we describe the design/synthesis/evaluation of 12 non‐covalent potential Pin1‐PROTACs ( P1 – P12 ) based on reversible peptidomimetic ligand and in a prodrug form to allow cell permeability. Despite rational design, stability and measurable target engagement, P1 – P12 displayed none or very limited degradation activity, with the most active molecule, P3 , achieving only 39% of Pin1 depletion in MM cells. To confirm Pin1 degradability in MM, MM1.R cells were treated with the covalent PROTAC P1D‐34 , which induced robust dose‐dependent degradation (DC 50 = 3.16 µM, D MAX = 90%). Overall, while demonstrating the feasibility of Pin1 depletion in MM, this work highlights the challenge of achieving effective Pin1 degradation with non‐covalent micromolar ligands, underscores the current advantage of covalent engagement, and provides a foundation for the future development of non‐covalent Pin1 degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CNRS, BioCIS, CY Cergy Paris Université, Cergy Pontoise, France.
- CNRS, BioCIS, Université Paris-Saclay, Orsay, France.
- CPCV, ENS, PSL, CNRS, Sorbonne Université, Paris, France.
ORCID-Profile: Lorenzo Meneghelli, Ji-Hyung Choi, Sami Mohammed Daddi Moussa, Simon Nadal, Ludovic Carlier, Maud Larregola, Julien Pytkowicz, Chiara Zanato
Förderung
- ANR (Agence Nationale de la Recherche)
- CY Initiative
Zitieren
APA
Meneghelli, L., Davidson, S., Choi, J. H., Moussa, S. M. D., Nadal, S., Ravault, D., Carlier, L., Larregola, M., Pytkowicz, J., & Zanato, C. (2026). Exploring Non‐Covalent Pin1‐PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71850
Vancouver
Meneghelli L, Davidson S, Choi JH, Moussa SMD, Nadal S, Ravault D, et al. Exploring Non‐Covalent Pin1‐PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71850
BibTeX
@article{Meneghelli2026,
author = {Meneghelli, Lorenzo and Davidson, Stephanie and Choi, Ji-Hyung and Moussa, Sami Mohammed Daddi and Nadal, Simon and Ravault, Delphine and Carlier, Ludovic and Larregola, Maud and Pytkowicz, Julien and Zanato, Chiara},
title = {Exploring Non‐Covalent Pin1‐PROTACs Insights Into Degradation Efficiency in Multiple Myeloma Cell Line},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.71850}
}
EUVIMED